of care. These physicians tell me that, at every meeting, they are told they aren't practicing modern medicine if they don't routinely check for mutations of gene X, despite little evidence that drugs targeting gene X improve outcomes. A horde of commercial entities inform us that their molecular profiling services will lift our practice from the dark ages and enlighten us with the wisdom to provide the best possible care for our patients. However, these entities largely ignore the fact that the vast majority of biomarkers in these profiles have not been clinically validated.
Even NCCN can sometimes jump on the bandwagon. The updated NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for NSCLC now recommend that, "EGFR ± ALK testing should be conducted as part of multiplex/ next-generation sequencing." 1 The guidelines list potential targets beyond EGFR and ALK, along with "available" agents aimed at these targets, even though the activity of several of these agents in NSCLC is currently supported only by single-patient case reports. I am not an oncologic Luddite, but the wastebasket of oncologic history is strewn with rational strategies that didn't pan out when rigorously evaluated in prospective clinical trials.
That our increasing understanding of cancer biology offers great promise for turning cancer into a chronic disease through personalized therapy is not in doubt. But before getting everyone's hopes up and spending billions of dollars on nonvalidated biomarker assays and the treatments derived from them, we need to do the work to ensure that we are getting the right drug to the right patient. This does not mean we need to work out every detail of an agent's use before rolling it out, but it does mean we need to ensure the analytic and clinical validity of the test and to define specific populations in which the agents have significant clinical utility.
Currently, broad molecular profiling of cancer remains a research tool, which is best used to direct patients to ongoing clinical trials. "One-off" treatments based on isolated molecular findings are unlikely to benefit patients and will not advance the field. Rationally conceived "master protocols" are being developed by both academics and industry, which will direct patients into specific clinical trials based on the molecular profile of their tumor. Some such studies are already underway and should be supported through robust patient enrollment.
We have learned that the therapeutic relevance of putative biomarkers depends on their context. Thus, large registries are needed to capture the vast amounts of molecular and clinical data that will allow us to sort through the complexities of cancer biology. It is only through such rigorous efforts that we will ultimately justify the price of hope.
